Carna Biosciences, Inc. (TYO:4572)
Japan
· Delayed Price · Currency is JPY 280.00
-4.00 (-1.41%)
May 2, 2025, 3:30 PM JST
Carna Biosciences Income Statement
Financials in millions JPY. Fiscal year is January - December.
Millions JPY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 636 | 1,625 | 1,386 | 2,017 | 1,133 | Upgrade
|
| Revenue Growth (YoY) | -60.86% | 17.24% | -31.28% | 78.02% | -64.67% | Upgrade
|
| Cost of Revenue | 171 | 175 | 171 | 135 | 192 | Upgrade
|
| Gross Profit | 465 | 1,450 | 1,215 | 1,882 | 941 | Upgrade
|
| Selling, General & Admin | 655 | 664 | 603 | 572 | 524 | Upgrade
|
| Research & Development | 1,886 | 1,903 | 1,882 | 1,841 | 1,474 | Upgrade
|
| Operating Expenses | 2,541 | 2,567 | 2,485 | 2,413 | 1,998 | Upgrade
|
| Operating Income | -2,076 | -1,117 | -1,270 | -531 | -1,057 | Upgrade
|
| Interest Expense | -3 | -4 | -6 | -4 | -7 | Upgrade
|
| Interest & Investment Income | 14 | - | - | - | - | Upgrade
|
| Currency Exchange Gain (Loss) | 26 | - | - | 14 | -9 | Upgrade
|
| Other Non Operating Income (Expenses) | -42 | -5 | -3 | -3 | -5 | Upgrade
|
| EBT Excluding Unusual Items | -2,081 | -1,126 | -1,279 | -524 | -1,078 | Upgrade
|
| Asset Writedown | -93 | -4 | -44 | -9 | -26 | Upgrade
|
| Other Unusual Items | - | - | - | - | 1 | Upgrade
|
| Pretax Income | -2,174 | -1,130 | -1,323 | -533 | -1,103 | Upgrade
|
| Income Tax Expense | 4 | 22 | 26 | 1 | 8 | Upgrade
|
| Net Income | -2,178 | -1,152 | -1,349 | -534 | -1,111 | Upgrade
|
| Net Income to Common | -2,178 | -1,152 | -1,349 | -534 | -1,111 | Upgrade
|
| Shares Outstanding (Basic) | 18 | 17 | 14 | 13 | 12 | Upgrade
|
| Shares Outstanding (Diluted) | 18 | 17 | 14 | 13 | 12 | Upgrade
|
| Shares Change (YoY) | 6.61% | 23.37% | 7.26% | 3.22% | 10.64% | Upgrade
|
| EPS (Basic) | -121.61 | -68.57 | -99.06 | -42.06 | -90.33 | Upgrade
|
| EPS (Diluted) | -121.61 | -68.57 | -99.06 | -42.06 | -90.33 | Upgrade
|
| Free Cash Flow | -1,387 | -1,688 | -834 | -1,577 | -1,324 | Upgrade
|
| Free Cash Flow Per Share | -77.44 | -100.48 | -61.24 | -124.22 | -107.65 | Upgrade
|
| Gross Margin | 73.11% | 89.23% | 87.66% | 93.31% | 83.05% | Upgrade
|
| Operating Margin | -326.41% | -68.74% | -91.63% | -26.33% | -93.29% | Upgrade
|
| Profit Margin | -342.45% | -70.89% | -97.33% | -26.47% | -98.06% | Upgrade
|
| Free Cash Flow Margin | -218.08% | -103.88% | -60.17% | -78.19% | -116.86% | Upgrade
|
| EBITDA | -2,045 | -1,082 | -1,237 | -512 | -1,045 | Upgrade
|
| EBITDA Margin | - | -66.59% | -89.25% | -25.38% | -92.23% | Upgrade
|
| D&A For EBITDA | 31 | 35 | 33 | 19 | 12 | Upgrade
|
| EBIT | -2,076 | -1,117 | -1,270 | -531 | -1,057 | Upgrade
|
| EBIT Margin | - | -68.74% | -91.63% | -26.33% | -93.29% | Upgrade
|
Updated Feb 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.